Table 3. Risk ratio of Rheumatoid Factor, Anti-cyclic citrullinated peptide antibodies and sIL-15 levels associated with a higher mean disease activity or need for intensive treatment during the follow-up.
Mean DAS28 | Intensive DMARD treatment | |||
Risk ratio [95% CI] | p | Risk ratio [95% CI] | p | |
Rheumatoid Factor + | 1.13 [0.63–2.05] | n.s. | 1.26 [0.78–2.04] | n.s. |
ACPA + | 1.57 [0.92–2.67] | n.s. | 0.91 [0.56–1.48] | n.s. |
sIL-15>20 pg/ml | 0.92 [0.66–1.30] | n.s. | 2.38 [1.54–3.69] | <0.001 |
Female gender | 2.68 [1.05–6.81] | 0.039 | - | n.s. |
Age at DO: <40 y-o | Ref. | - | - | n.i. |
40–55 | 1.60 [0.47–5.44] | n.s. | - | n.i. |
55–70 | 3.37 [1.07–10.60] | 0.038 | - | n.i. |
>70 | 6.50 [2.18–19.39] | 0.001 | - | n.i. |
DAS28: 28-joint count Disease Activity Score. DMARD: disease modifying anti-rheumatic drugs. CI: confidence interval. ACPA: anti-cyclic citrullinated peptide antibodies; n.s.: not significant; n.i.: not included. DO: disease onset. Ref.: reference variable.